Professional technology integration to support the entire R&D process

Immuno-oncology (I-O) assay optimization is a crucial stage in the systematic improvement and validation of precision, accuracy, specificity, and robustness after method establishment. This process aims to ensure that the assay performance meets the reliability and stability requirements for its intended use (such as candidate molecule functional ranking or potency determination) and lays the foundation for subsequent formal method validation. This document, based on the fundamental scientific principles of the Chinese Pharmacopoeia (ChP) regarding bioassay methods (such as General Chapter 9401 "Guiding Principles for Validation of In Vitro Bioactivity/Potency Assay Methods for Biological Products") and analytical method validation (General Chapter <9101>), elucidates the core strategies for I-O assay optimization..

The ultimate goal of optimization is to achieve a "validation state" for the assay. Its core performance indicators are closely related to the guidelines of the Chinese Pharmacopoeia:

1.Precision: Through optimization, random errors in the assay are minimized, ensuring the repeatability (intra-plate/inter-plate) and intermediate precision of the results. This is a prerequisite for validation of the precision item in the pharmacopoeia.

2.Accuracy/Authenticity: By optimizing the system, ensure that the measured results (such as kill rate, IC₅₀) are as close as possible to their "true value." This makes it possible to validate the relative accuracy of pharmacopoeia measurements.

3.Specificity/Selectivity: By optimizing control settings and conditions, maximize the target-specific signal and minimize interference caused by non-specific immune activation, cytotoxicity, or matrix effects. This is the core of pharmacopoeia specificity validation.

4.Robustness: Consciously test minor variations of key operating parameters during the optimization phase to ensure the robustness of the method in routine use. This directly corresponds to the robustness assessment in pharmacopoeias.

Optimization is a planned, data-driven iterative process, not arbitrary adjustments. It should be based on risk assessment, focusing on the variables that have the greatest impact on the results.

1. Refined Regulation of Biological Parameters

Effective Cell State Optimization:

Goal: Ensure the consistency of activity and function of immune cells (such as T cells, PBMCs), which is the basis of precision 

Strategy:

Donor and Preparation: If using PBMCs, optimize donor selection (e.g., multiple donors), resuscitation procedures, and resting times to reduce donor-to-donor variability.

Pre-activation Standardization: For T cells requiring pre-activation, strictly standardize activation reagents (e.g., CD3/CD28 antibody concentration), cytokine (e.g., IL-2) concentrations, and culture time.

Target Cell Status Optimization: 

Goal: Ensure target cells (e.g., reporter gene tumor cells) are in a stable, homogeneous, and sensitive state.

Strategy: Control passage number, optimize cell confluence at seeding, and regularly monitor reporter gene expression stability (e.g., luciferase activity).

Co-culture System Core Parameter Optimization:

Effective-to-Target Ratio: Perform gradient experiments, selecting the ratio with the steepest dose-response curve before reaching the plateau effect to obtain the largest detection window and sensitivity.

Co-culture Time: Perform time-kinetic experiments, selecting the time point where the signal reaches the plateau phase and the coefficient of variation (CV) is minimal, avoiding insufficient signal due to insufficient time or increased background due to excessive time.

2. Standardization of Detection and Reading Components

Detection Reagents: For commercially available kits (such as MSD/electrochemiluminescence plates for cytokine detection, LDH detection reagents) or key components (such as luciferase substrates), the optimal signal-to-noise ratio concentration and incubation time must be determined using checkerboard titration, and the brand and catalog number must be standardized.

Sample Addition and Operation Procedures:

Liquid Handling: Optimize the sample addition sequence, mixing method, and intensity to reduce operational variability.

Environmental Control: Define and control the CO₂ concentration, humidity, and operating temperature of the incubator; these are inherent requirements for pharmacopoeia durability testing.

After the assay has undergone the above systematic optimization, the following "pre-validation" standards should be met before entering the formal method validation stage:

1.Stable performance indicators: In three consecutive independent experiments, the variation of key parameters (such as maximum killing rate, EC₅₀/IC₅₀, Z' factor) is within acceptable limits.

2.Reliable control system: The positive and negative control signals are clearly and stably separated.

3.Passing the initial robustness test: Minor variations in 1-2 key steps (such as the post-cell seeding resting time) are tested, and the results do not show significant deviations.

Optimization of immuno-oncology assays is a refined and forward-looking process based on the guiding principles of the Chinese Pharmacopoeia. Its core idea is to proactively improve and confirm the precision, accuracy, specificity, and robustness factors that need to be examined in the validation stage in the later stages of development. Systematic parameter optimization and troubleshooting can significantly improve the robustness and reliability of assay methods, thus providing a solid technical guarantee for successful validation by rigorous pharmacopoeia standard methods and their application in drug screening and quality control. Optimization records should be detailed and complete, serving as an important document for method lifecycle management.